RE:RE:Started a PositionThanks Capharnaum, for laying out the quarterly revenues. Numbers are only going higher quarter, after quarter, after quarter. All the while, Hamed not taking a single dollar in salary. In fact, he has put in cash in the business at every equity financing. Literally paying out of his own pocket to be working at WELL! I'm sure you will be returned many fold.
The road to $200MM per quarter is clear. Organic growth, especially from Circle Medical and WISP and inorganic growth with more acquisitions big and small. Thereafter, the road to $500MM per quarter is also clear. Then the road to $1Bn per quarter is clear. Look, long term shareholder here, the canadian and US primary healthcare market still highly fragmented, with opportunity aplenty to consolidate those free cash flowing assets over the next couple of decades.
WELL is going to be the Constellation Software of Healthcare. But even Constellation took time to get to the behemoth it is today. And note, even it its size, Constellation is growing because industrial and service software remains highly fragmented. Same goes for WELL with primary healthcare. Even 10 or 20 years from now, WELL will still have lots of opportunities for growth.
Revenue is only going higher from here, as it has been. Free cash flow increasing as well. Unfortunately, the company gets very little credit in the market for being significantly different that its "peer group". Who in the peer group has positive growing EBITDA. Who in the peer group has positive, growing free cash flows? Who in the peer group has proven management and rock solid cornerstone investors? Who has both clinics and digital? This company, not the stock but the underlying business, has so much going for it that is currently not reflected in the stock. That's okay, at some point it will be.
I hope Hamed and team are finding some opportunities in the market at discounted prices given the current volatility. Hopefully they can transact on those deals at advantagous valuations. Grow revenue even faster.